| Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis DM Black, PD Delmas, R Eastell, IR Reid, S Boonen, JA Cauley, ... New England Journal of Medicine 356 (18), 1809-1822, 2007 | 3900 | 2007 |
| Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study JY Reginster, S Adami, P Lakatos, M Greenwald, JJ Stepan, SL Silverman, ... Annals of the rheumatic diseases 65 (5), 654-661, 2006 | 517 | 2006 |
| Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised … DL Kendler, F Marin, CAF Zerbini, LA Russo, SL Greenspan, V Zikan, ... The Lancet 391 (10117), 230-240, 2018 | 508 | 2018 |
| Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open … BL Langdahl, C Libanati, DB Crittenden, MA Bolognese, JP Brown, ... The Lancet 390 (10102), 1585-1594, 2017 | 397 | 2017 |
| Epidemiology and diagnosis of hypoparathyroidism BL Clarke, EM Brown, MT Collins, H Jüppner, P Lakatos, MA Levine, ... The Journal of Clinical Endocrinology & Metabolism 101 (6), 2284-2299, 2016 | 341 | 2016 |
| The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study S Papapoulos, K Lippuner, C Roux, CJF Lin, DL Kendler, EM Lewiecki, ... Osteoporosis international 26, 2773-2783, 2015 | 321 | 2015 |
| Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study M Mannstadt, BL Clarke, T Vokes, ML Brandi, L Ranganath, WD Fraser, ... The lancet Diabetes & endocrinology 1 (4), 275-283, 2013 | 304 | 2013 |
| The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON‐Pivotal Fracture Trial (PFT) DM Black, IR Reid, JA Cauley, F Cosman, PC Leung, P Lakatos, ... Journal of Bone and Mineral Research 30 (5), 934-944, 2015 | 293 | 2015 |
| Vitamin D and estrogen receptor gene polymorphisms in type 2 diabetes mellitus and in android type obesity G Speer, K Cseh, G Winkler, P Vargha, E Braun, I Takacs, P Lakatos European journal of endocrinology 144 (4), 385-389, 2001 | 173 | 2001 |
| Effect of gypsum on proliferation and differentiation of MC3T3-E1 mouse osteoblastic cells Á Lazáry, B Balla, JP Kósa, K Bácsi, Z Nagy, I Takács, PP Varga, G Speer, ... Biomaterials 28 (3), 393-399, 2007 | 135 | 2007 |
| High serum osteoprotegerin and low RANKL in primary biliary cirrhosis F Szalay, D Hegedus, PL Lakatos, I Tornai, E Bajnok, K Dunkel, P Lakatos Journal of hepatology 38 (4), 395-400, 2003 | 135 | 2003 |
| Serum interleukin-6 and bone metabolism in patients with thyroid function disorders P Lakatos, J Foldes, C Horvath, L Kiss, A Tatrai, I Takacs, G Tarjan, ... The Journal of Clinical Endocrinology & Metabolism 82 (1), 78-81, 1997 | 135 | 1997 |
| Serum 25 (OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis Z Kiss, C Ambrus, C Almasi, K Berta, G Deák, P Horonyi, I Kiss, P Lakatos, ... Nephron Clinical Practice 117 (4), 373-378, 2011 | 123 | 2011 |
| Thyroid hormones: beneficial or deleterious for bone? P Lakatos Calcified tissue international 73, 205-209, 2003 | 119 | 2003 |
| Common mutations of ATP7B in Wilson disease patients from Hungary G Firneisz, PL Lakatos, F Szalay, C Polli, TT Glant, P Ferenci American journal of medical genetics 108 (1), 23-28, 2002 | 118 | 2002 |
| Decreased bone density, elevated serum osteoprotegerin, and β‐cross‐laps in Wilson disease D Hegedus, V Ferencz, PL Lakatos, S Mészáros, P Lakatos, C Horvath, ... Journal of Bone and Mineral Research 17 (11), 1961-1967, 2002 | 108 | 2002 |
| Time to onset of bisphosphonate‐related osteonecrosis of the jaws: a multicentre retrospective cohort study PPL Fung, G Bedogni, A Bedogni, A Petrie, S Porter, G Campisi, J Bagan, ... Oral Diseases 23 (4), 477-483, 2017 | 105 | 2017 |
| Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial P Geusens, F Marin, DL Kendler, LA Russo, CAF Zerbini, S Minisola, ... Journal of Bone and Mineral Research 33 (5), 783-794, 2018 | 99 | 2018 |
| Serum 25 (OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. I Mucsi, C Almasi, G Deak, A Marton, C Ambrus, K Berta, P Lakatos, ... Clinical nephrology 64 (4), 2005 | 95 | 2005 |
| Prävention der Kortikosteroid-induzierten Osteoporose durch Alfacalcidol P Lakatos, Z Nagy, L Kiss, C Horvath, I Takacs, J Foldes, G Speer, ... Zeitschrift für Rheumatologie 59, I48-I52, 2000 | 95 | 2000 |
